Venetoclax (ABT-199) is a BH3 mimetic which selectively binds to BCL-2 and acts as a selective BCL-2 inhibitor (BCL-2i).15 Recent clinical studies determined that Venetoclax improved survival in adults with chronic lymphocytic leukemia (CLL) and AML (in combination with azacytidine or decitabine).16 This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.